JP2011511022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511022A5 JP2011511022A5 JP2010545422A JP2010545422A JP2011511022A5 JP 2011511022 A5 JP2011511022 A5 JP 2011511022A5 JP 2010545422 A JP2010545422 A JP 2010545422A JP 2010545422 A JP2010545422 A JP 2010545422A JP 2011511022 A5 JP2011511022 A5 JP 2011511022A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- ono
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 6
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010030043 Ocular hypertension Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 208000022901 Reynold syndrome Diseases 0.000 claims 2
- 208000016717 Reynolds syndrome Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000004097 bone metabolism Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CCCCCN(C*)*C Chemical compound CCCCCN(C*)*C 0.000 description 41
- WWHKLHQUVWAZHR-UHFFFAOYSA-N CCC1[O](C)CCC1O Chemical compound CCC1[O](C)CCC1O WWHKLHQUVWAZHR-UHFFFAOYSA-N 0.000 description 1
- BEBZSNBEMQNXQK-GGZOMVNGSA-N CCCCC(OC[C@H](CO[C@@H]12)[C@H]1OCC2=O)=O Chemical compound CCCCC(OC[C@H](CO[C@@H]12)[C@H]1OCC2=O)=O BEBZSNBEMQNXQK-GGZOMVNGSA-N 0.000 description 1
- HGBAJKXNBQUWSB-GRQBKTHUSA-N C[C@H]1C2OCCC2OC1 Chemical compound C[C@H]1C2OCCC2OC1 HGBAJKXNBQUWSB-GRQBKTHUSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US694608P | 2008-02-07 | 2008-02-07 | |
| US61/006,946 | 2008-02-07 | ||
| PCT/EP2009/050416 WO2009098113A1 (en) | 2008-02-07 | 2009-01-15 | Nitric oxide donor compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011511022A JP2011511022A (ja) | 2011-04-07 |
| JP2011511022A5 true JP2011511022A5 (https=) | 2012-03-01 |
| JP5441928B2 JP5441928B2 (ja) | 2014-03-12 |
Family
ID=40445685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545422A Expired - Fee Related JP5441928B2 (ja) | 2008-02-07 | 2009-01-15 | 一酸化窒素供与化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8003811B2 (https=) |
| EP (1) | EP2238143B1 (https=) |
| JP (1) | JP5441928B2 (https=) |
| CA (1) | CA2706082C (https=) |
| ES (1) | ES2393049T3 (https=) |
| WO (1) | WO2009098113A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| KR101794363B1 (ko) | 2009-12-11 | 2017-11-06 | 디에스엠 아이피 어셋츠 비.브이. | 반추동물에서의 메탄 방출을 감소시키고/감소시키거나 반추동물 수익성을 개선시키기 위한 사료중의 니트로옥시 알칸산 및 이의 유도체 |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
| US10154981B2 (en) | 2011-05-26 | 2018-12-18 | Dsm Ip Assets B.V. | Use of a feed composition for reducing methane emission in ruminants, and/or to improve ruminant performance |
| CN105026402A (zh) * | 2013-03-05 | 2015-11-04 | 阿彻丹尼尔斯米德兰德公司 | 异己糖醇单三氟甲磺酸酯及其合成方法 |
| EP2986288B1 (en) * | 2013-04-18 | 2017-04-12 | Nicox Science Ireland | Quinone based nitric oxide donating compounds for ophthalmic use |
| WO2016022944A1 (en) * | 2014-08-08 | 2016-02-11 | Central Michigan University | Flame retardants from renewable resources |
| US10610509B2 (en) | 2014-11-19 | 2020-04-07 | Nicox S.A. | Combinations of prostaglandins and nitric oxide donors |
| EP3088388A1 (en) | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
| WO2018224419A1 (en) | 2017-06-06 | 2018-12-13 | Nicox S.A. | Nitric oxide donating isomannide derivatives |
| JP7596257B2 (ja) | 2018-08-06 | 2024-12-09 | ニコックス エス．エー． | 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 |
| US11779560B2 (en) * | 2020-03-28 | 2023-10-10 | Coeurative, Inc. | Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60149521A (ja) * | 1984-01-18 | 1985-08-07 | Eisai Co Ltd | 高眼圧・緑内障治療・予防用点眼剤 |
| DE3831949A1 (de) | 1988-09-20 | 1990-03-22 | Mack Chem Pharm | Arzneimittel |
| ES2142773B1 (es) * | 1998-10-07 | 2001-01-01 | Lacer Sa | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida. |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| ES2258365B1 (es) * | 2003-10-03 | 2007-12-01 | Lacer, S.A. | Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos. |
| IE20070934A1 (en) * | 2007-12-21 | 2009-06-24 | Trinity College Dublin | Efficient aspirin prodrugs |
-
2009
- 2009-01-15 ES ES09708682T patent/ES2393049T3/es active Active
- 2009-01-15 EP EP09708682A patent/EP2238143B1/en not_active Not-in-force
- 2009-01-15 US US12/744,168 patent/US8003811B2/en active Active
- 2009-01-15 JP JP2010545422A patent/JP5441928B2/ja not_active Expired - Fee Related
- 2009-01-15 CA CA2706082A patent/CA2706082C/en active Active
- 2009-01-15 WO PCT/EP2009/050416 patent/WO2009098113A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511022A5 (https=) | ||
| JP2013510123A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2009536191A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| JP2013523896A5 (https=) | ||
| JP2008525416A5 (https=) | ||
| JP2010514831A5 (https=) | ||
| JP2008195730A5 (https=) | ||
| JP2008531604A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2008543854A5 (https=) | ||
| JP2011527334A5 (https=) | ||
| JP2011502174A5 (https=) | ||
| JP2010510237A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| JP2012525393A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| JP2007530577A5 (https=) | ||
| JP2014532728A5 (https=) | ||
| JP2009530398A5 (https=) | ||
| RU2013156687A (ru) | Антагонисты рецептора св1 |